论文部分内容阅读
目的研究KAI1蛋白在子宫内膜癌组织中的表达及其与临床病理参数的关系。方法采用免疫组织化学SP法检测50例子宫内膜癌、20例不典型增生子宫内膜、10例正常增生期子宫内膜组织中KAI1蛋白的表达,并分析其与子宫内膜癌的临床病理参数的关系。结果KAI1蛋白在正常子宫内膜、子宫内膜非典型增生、子宫内膜癌中的阳性表达率逐渐降低,子宫内膜癌中KAI1蛋白的阳性表达率明显低于非典型增生组及正常子宫内膜组,差异有统计学意义(P=0.016)。子宫内膜癌中KAI1蛋白的表达与临床分期、组织学分级、肌层浸润深度和淋巴结转移相关,差异有统计学意义(P<0.05)。结论KAI1蛋白在子宫内膜癌的恶性进展过程中表达逐渐下降,其可能成为估计子宫内膜癌恶性程度的生物学指标。
Objective To study the expression of KAI1 in endometrial carcinoma and its relationship with clinicopathological parameters. Methods The expression of KAI1 protein in 50 cases of endometrial carcinoma, 20 cases of atypical hyperplasia endometrium and 10 cases of normal proliferative endometrium was detected by immunohistochemical SP method. The clinical and pathological features of endometrial carcinoma The relationship between the parameters. Results The positive rate of KAI1 protein in normal endometrium, endometrial dysplasia and endometrial carcinoma decreased gradually. The positive rate of KAI1 protein in endometrial carcinoma was significantly lower than that in atypical hyperplasia and normal uterus Membrane group, the difference was statistically significant (P = 0.016). The expression of KAI1 protein in endometrial carcinoma was correlated with clinical stage, histological grade, depth of myometrial invasion and lymph node metastasis (P <0.05). Conclusion The expression of KAI1 protein in malignant progression of endometrial carcinoma gradually decreases, which may be a biological indicator to evaluate the malignancy of endometrial carcinoma.